Sierra Oncology Reports NDA Submission of Momelotinib to the US FDA for the Treatment of Myelofibrosis
- The NDA submission was based on the multiple P-II & III studies including (MOMENTUM) study to evaluate momelotinib in patients with myelofibrosis who were symptomatic & anemic, and prior treated with the US FDA-approved JAK inhibitor. The product is expected to be available in 2023
- The P-III (MOMENTUM) study's 1EPs is a TSS reduction of >50% over the 28 days vs baseline TSS, while the 2EPs included a TI rate of>12wks. before the end of 24wk. with Hgb levels of 8 g/dL, SRR based on splenic volume reduction of >35% @24wk.
- Momelotinib is an ACVR1 / ALK2, JAK1, JAK2 inhibitor that is being studied for myelofibrosis in symptomatic, anaemic patients who have previously been treated with an approved JAK inhibitor
Ref: Businesswire | Image: Sierra Oncology
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
